Eligibilty

Gender



Age Group



More options for age range

Dates

Names

Showing 1 - 5 of 226 results
Page 1 of 46   

Caffeine and Motor Memory

Principal Investigator: Kelly Cole, PhD

Department:Health and Human Physiology

We are currently recruiting healthy participants for a research study that examines learning and memory of a fine motor skill. If you choose to participate, you will visit the laboratory for two consecutive days, for 30-60 minutes each day. During these sessions, you will complete a fine motor task repeatedly. If you are interested, please contact Sara at sara-hussain@uiowa.edu

age group:18 to 30 years trial start date:April 14, 2014
Gender Preference:none Trial End Date: October 14, 2014
Contact Info:

Sara at sara-hussain@uiowa.edu

Keywords: dexterity ; grasp ; memory ; motor learning

Caffeine and Motor Memory

Principal Investigator:Kelly Cole, PhD

Department:Health and Human Physiology

We are currently recruiting healthy participants who consume less than 500mg of caffeine per week for a research study that examines the effect of caffeine on motor memory. If you choose to participate, you will be assigned to one of two groups: one group will receive a caffeine pill after learning a new motor skill, and another group will receive a placebo pill after learning a new motor skill. All subjects will visit the laboratory for two consecutive days, for 30-60 minutes each day. During these sessions, you will complete a fine motor task repeatedly.  If interested, please contact Sara at sara-hussain@uiowa.edu

age group:18 to 30 years trial start date:April 14, 2014
Gender Preference:none Trial End Date: October 14, 2014
Contact Info:

Sara at sara-hussain@uiowa.edu

Keywords: caffeine ; dexterity ; memory ; motor learning

Aspire

Principal Investigator: Sif Hansdottir, MD

Department:Department or Field of Study

Aspire A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso®(Treprostinil) Inhalation Solution 

Primary Outcome Measures: Describe the type and incidence of oro-/nasopharyngeal and pulmonary adverse events that may be associated with current or recent treatment with Tyvaso for PAH and with patients not treated with Tyvaso for PAH.

Please refer to www.clinicaltrials.gov for more information identifier NCT01266265

age group:1 to 99 years trial start date:April 11, 2011
Gender Preference:none Trial End Date: January 21, 2015
Contact Info:

Pulmonary Hypertension Program

Cynthia Larew RN 319-356-1028  pager # 2123

cynthia-larew@uiowa.edu

Keywords: Enter keyword ; Heart ; inhaled prostacyclin ; observational study ; PAH ; Pulmonary Arterial Hypertension ; pulmonary hypertension ; treprostinil sodium ; Tyvaso

TAH-t Post Markey Surveillance Study

Principal Investigator:Jennifer Goerbig-Campbell, MD

Department:Department or Field of Study

The purpose of this study is to demonstrate that the results achieved in the original pivotal clinical investigation of 81 subjects from five clinical sites are generalizable to new clinical sites that complete the staff training defined in the SynCardia Systems, Inc. Training Manual and who enroll subjects who meet the intended use defined in the product Instructions for Use.

 

Please refer to www.clinicaltrials.gov identifier NCT00614510 for more information.

age group:18 to 99 years trial start date:August 1, 2006
Gender Preference:none Trial End Date: January 31, 2015
Contact Info:

Cardiomyopathy Treatment Program

Page Scovel, RN

phone:  319-356-1028

fax: 319-356-7087

email: page-scovel@uiowa.edu

Keywords: Artificial heart ; cardiac disease ; Cardiomyopathy ; CHF ; Congestive heart failure ; Heart ; heart disease ; Heart failure ; Mechanical circulatory support

Darbepoetin Alfa in Anemic Subjects with Advanced Stage Non-small Cell Lung Cancer

Principal Investigator: Taher Abu Hejleh, MD

Department:Department or Field of Study

Participants in this research study have been diagnosed with advanced stage non-small cell lung cancer and are currently receiving chemotherapy. The purpose of this study is to determine the safety of a drug called darbepoetin alfa. Approximately 3000 people will be enrolled in this study worldwide. Study involvement will last until the conclusion of the study.

age group:18 to 99 years trial start date:December 1, 2009
Gender Preference:none Trial End Date: December 1, 2019
Contact Info:

Karen Parrott, 319-353-6347

Keywords: advanced stage ; cancer ; chemotherapy ; darbepoetin alfa ; hohl ; IRB#200903681 ; non-small cell lung cancer ; phase 3 ; phase III
Page 1 of 46
« 1 2 3 4 5  ... » 
Results per page
5 | 15 | 25

Clinical Research Studies

Filter By Started within
Show trials started in last 1 month
Your Selections

We'd welcome your feedback!

Please help us improve your experience on our website by completing a brief survey

Yes, I'll give feedback No, Thanks

x